Vaccination of prostate cancer patients with MUC-2-KLH conjugate plus the immunological adjuvant QS21: a trial examining the immunogenicity of glycosylated MUC-2-KLH peptide conjugate vaccine
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Prostate cancer vaccine (Primary) ; QS 21
- Indications Prostate cancer
- Focus Pharmacodynamics; Therapeutic Use
- 31 Jan 2013 Biomarkers information updated
- 09 Jul 2008 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
- 09 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.